The Bone Core of the Program Project will provide shared facilities and services for processing and interpretation of tissues from the animal models utilized in all projects of the program. The overall goal of the core facility is to provide centralized histologic and image analysis support for investigators in the project. The following services will be provided: experimental design/consultation regarding endpoint analyses for histologic specimens, processing of osseous tissues for histologic analysis (decalcified and undecalcified sections, bone histomorphometric analysis of osseous sections (i.e. interpretation), and histologic analysis of soft tissue metastases or other soft tissue lesions with their pathologic diagnosis. In addition to histologic support, the core will provide services of FAXITRON microradiography and peripheral QCT. The bone core will continue providing expertise that includes the processing of soft tissue specimens and decalcified hard tissue specimens in paraffin in addition to processing undecalcified osseous specimens using plastic embedding techniques. Investigators will be provided with training and assistance in static and dynamic bone histomorphometric analysis. Core support of these services will promote efficiency of specimen analysis and facilitate interactions between projects through the similar model systems and their common analyses. A significant benefit to the program as a group will be a standardized format for analysis of specimens from the common animal models that will be using different experimental approaches/targets (e.g. CCL2, SDF-1 &CXCR4, wnts, Dkk-1, and PTHrP). This will provide valuable information that can be shared and compared across the projects in the program.

Public Health Relevance

(Seeinstructions): The Bone Core of the Program Project will provide shared facilities and services for processing and interpretation of tissues from the animal models utilized in all projects of the program. The overall goal of the core facility is to provide centralized histologic and image analysis support for investigators in the project. Such a standardized format with provide valuable information and consistency across the projects in the program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA093900-06A1
Application #
7659016
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (J1))
Project Start
2009-05-01
Project End
2014-04-30
Budget Start
2009-07-03
Budget End
2010-04-30
Support Year
6
Fiscal Year
2009
Total Cost
$165,835
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Miller, Dannah R; Tzeng, Cherng-Chyi; Farmer, Trey et al. (2018) Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Cancer Lett 436:96-108
Machioka, Kazuaki; Izumi, Kouji; Kadono, Yoshifumi et al. (2018) Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget 9:16185-16196
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705

Showing the most recent 10 out of 228 publications